Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
CLI Pipeline Drugs Market Overview
Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.
The CLI pipeline drugs market research report provides comprehensive information on the therapeutics under development for CLI, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for CLI and features dormant and discontinued projects.
CLI Pipeline Drugs Market Segmentation by Targets
Some of the targets of the CLI pipeline drugs market are Hepatocyte Growth Factor, E Selectin, Fibroblast Growth Factor 2, Prostaglandin E2 Receptor EP1 Subtype, Soluble Guanylate Cyclase, and Telomerase Reverse Transcriptase.
CLI Pipeline Drugs Market Analysis, by Targets
For more CLI pipeline drugs market target insights, download a free report sample
CLI Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the CLI pipeline drugs market are Hepatocyte Growth Factor Activator, E Selectin Activator, Fibroblast Growth Factor 2 Activator, Prostaglandin E2 Receptor EP1 Subtype Agonist, Soluble Guanylate Cyclase Activator, and Telomerase Reverse Transcriptase Activator.
CLI Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the CLI pipeline drugs market, download a free report sample
CLI Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the CLI pipeline drugs market are intramuscular, intravenous, intraarterial, intraarticular, intracoronary, intrathecal, intravascular, and subcutaneous.
CLI Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the CLI pipeline drugs market, download a free report sample
CLI Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the CLI pipeline drugs market are Cell Therapy, Gene Therapy, Biologic, Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, and Synthetic Peptide.
CLI Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the CLI pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the CLI pipeline drugs market are Ambulero Inc, Caladrius Biosciences Inc, Cynata Therapeutics Ltd, Helixmith Co Ltd, ID Pharma Co Ltd, Ixaka Ltd, Reven Holdings Inc, Antidote Therapeutics Inc, Athersys Inc, and Constant Therapeutics LLC.
CLI Pipeline Drugs Market Analysis, by Companies
To know more about the CLI pipeline drugs market companies, download a free report sample
CLI Pipeline Drugs Market Report Overview
Key Targets | Hepatocyte Growth Factor, E Selectin, Fibroblast Growth Factor 2, Prostaglandin E2 Receptor EP1 Subtype, Soluble Guanylate Cyclase, and Telomerase Reverse Transcriptase |
Key Mechanism of Actions | Hepatocyte Growth Factor Activator, E Selectin Activator, Fibroblast Growth Factor 2 Activator, Prostaglandin E2 Receptor EP1 Subtype Agonist, Soluble Guanylate Cyclase Activator, and Telomerase Reverse Transcriptase Activator |
Key Routes of Administration | Intramuscular, Intravenous, Intraarterial, Intraarticular, Intracoronary, Intrathecal, Intravascular, and Subcutaneous |
Key Molecule Types | Cell Therapy, Gene Therapy, Biologic, Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, and Synthetic Peptide |
Key Companies | Ambulero Inc, Caladrius Biosciences Inc, Cynata Therapeutics Ltd, Helixmith Co Ltd, ID Pharma Co Ltd, Ixaka Ltd, Reven Holdings Inc, Antidote Therapeutics Inc, Athersys Inc, and Constant Therapeutics LLC |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Critical limb ischemia (CLI).
- Reviews of pipeline therapeutics for CLI by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in CLI therapeutics and enlists all their major and minor projects.
- Evaluation of CLI therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Critical limb ischemia (CLI).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with the potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Critical limb ischemia (CLI).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding CLI pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Antidote Therapeutics Inc
Athersys Inc
Caladrius Biosciences Inc
Constant Therapeutics LLC
Cynata Therapeutics Ltd
Gurus BioPharm Inc
Helixmith Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
ImmuneCyte Inc
Ixaka Ltd
Kangstem Biotech Co Ltd
Libella Gene Therapeutics
New Beta Innovation Ltd
Orgenesis Inc
Pharmicell Co Ltd
Pluri Inc
Reven Holdings Inc
S.Biomedics Co Ltd
Taiwan Bio Therapeutics Co Ltd
Theratome Bio Inc
VESSL Therapeutics Ltd
Vivazome Therapeutics Pty Ltd
Yichang Humanwell Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the CLI pipeline drugs market?
Some of the key targets of the CLI pipeline drugs market are Hepatocyte Growth Factor, E Selectin, Fibroblast Growth Factor 2, Prostaglandin E2 Receptor EP1 Subtype, Soluble Guanylate Cyclase, and Telomerase Reverse Transcriptase.
-
What are the key mechanisms of action in the CLI pipeline drugs market?
Some of the key mechanisms of action in the CLI pipeline drugs market are Hepatocyte Growth Factor Activator, E Selectin Activator, Fibroblast Growth Factor 2 Activator, Prostaglandin E2 Receptor EP1 Subtype Agonist, Soluble Guanylate Cyclase Activator, and Telomerase Reverse Transcriptase Activator.
-
What are the key routes of administration in the CLI pipeline drugs market?
The key routes of administration in the CLI pipeline drugs market are intramuscular, intravenous, intraarterial, intraarticular, intracoronary, intrathecal, intravascular, and subcutaneous.
-
What are the key molecule types in the CLI pipeline drugs market?
The molecule types in the CLI pipeline drugs market are Cell Therapy, Gene Therapy, Biologic, Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, and Synthetic Peptide.
-
Which are the key companies in the CLI pipeline drugs market?
Some of the key companies in the CLI pipeline drugs market are Ambulero Inc, Caladrius Biosciences Inc, Cynata Therapeutics Ltd, Helixmith Co Ltd, ID Pharma Co Ltd, Ixaka Ltd, Reven Holdings Inc, Antidote Therapeutics Inc, Athersys Inc, and Constant Therapeutics LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.